ID

18472

Beschreibung

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00078260

Link

https://clinicaltrials.gov/show/NCT00078260

Stichworte

Versionen (2)
  1. 06.11.16 06.11.16 -
  2. 07.11.16 07.11.16 -
Hochgeladen am

7. November 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Non-Small Cell Lung Cancer NCT00078260

Englisch

Eligibility Non-Small Cell Lung Cancer NCT00078260

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of locally advanced or metastatic (stage iii or iv at entry) non-small cell lung cancer (nsclc) that is not amenable to curative therapy.
Beschreibung

Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | Disease Curative treatment Amenable | TNM clinical staging

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C1517927
UMLS CUI [2]
C0278987
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C3900053
UMLS CUI [4]
C3258246
patients must have been previously treated with one platinum-containing chemotherapy regimen for locally advanced or metastatic disease. patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.
Beschreibung

Prior Chemotherapy Platinum-Based Locally Advanced Malignant Neoplasm | Prior Chemotherapy Platinum-Based Metastatic Neoplasm | Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Chemotherapy Additional Recurrence

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C1514162
UMLS CUI [1,3]
C0677984
UMLS CUI [2,1]
C1514457
UMLS CUI [2,2]
C1514162
UMLS CUI [2,3]
C2939420
UMLS CUI [3,1]
C0600558
UMLS CUI [3,2]
C0392920
UMLS CUI [4]
C0085533
UMLS CUI [5,1]
C0392920
UMLS CUI [5,2]
C1524062
UMLS CUI [5,3]
C2825055
no more than two prior systemic anti-cancer therapies will be allowed.
Beschreibung

cancer treatment Systemic Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C1265611
prior radiation therapy is allowed to less than 25% of the bone marrow. prior radiation to the whole pelvis is not allowed. prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.
Beschreibung

prior radiation therapy Bone Marrow Percentage | prior radiation therapy Whole-Pelvis | prior radiation therapy Completed | Toxic effect Patient Recovered

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
UMLS CUI [2,1]
C0279134
UMLS CUI [2,2]
C3827467
UMLS CUI [3,1]
C0279134
UMLS CUI [3,2]
C0205197
UMLS CUI [4,1]
C0600688
UMLS CUI [4,2]
C0030705
UMLS CUI [4,3]
C0521108
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnancy.
Beschreibung

Pregnancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
breast-feeding.
Beschreibung

Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0006147
second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
Beschreibung

Second Primary Cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C0751623
inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.
Beschreibung

Aspirin Unable to discontinue Period | Non-Steroidal Anti-Inflammatory Agents Unable to discontinue Period

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C1548265
UMLS CUI [1,3]
C1948053
UMLS CUI [2,1]
C0003211
UMLS CUI [2,2]
C1548265
UMLS CUI [2,3]
C1948053
inability or unwillingness to take folic acid or vitamin b12 supplementation.
Beschreibung

Folate intake Unwilling | Vitamin B12 supplement Intake Unwilling

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0564428
UMLS CUI [1,2]
C0558080
UMLS CUI [2,1]
C3661610
UMLS CUI [2,2]
C1512806
UMLS CUI [2,3]
C0558080
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Non-Small Cell Lung Cancer NCT00078260

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | Disease Curative treatment Amenable | TNM clinical staging
Item
diagnosis of locally advanced or metastatic (stage iii or iv at entry) non-small cell lung cancer (nsclc) that is not amenable to curative therapy.
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C0278987 (UMLS CUI [2])
C0012634 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C3900053 (UMLS CUI [3,3])
C3258246 (UMLS CUI [4])
Prior Chemotherapy Platinum-Based Locally Advanced Malignant Neoplasm | Prior Chemotherapy Platinum-Based Metastatic Neoplasm | Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Chemotherapy Additional Recurrence
Item
patients must have been previously treated with one platinum-containing chemotherapy regimen for locally advanced or metastatic disease. patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.
boolean
C1514457 (UMLS CUI [1,1])
C1514162 (UMLS CUI [1,2])
C0677984 (UMLS CUI [1,3])
C1514457 (UMLS CUI [2,1])
C1514162 (UMLS CUI [2,2])
C2939420 (UMLS CUI [2,3])
C0600558 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C0085533 (UMLS CUI [4])
C0392920 (UMLS CUI [5,1])
C1524062 (UMLS CUI [5,2])
C2825055 (UMLS CUI [5,3])
cancer treatment Systemic Quantity
Item
no more than two prior systemic anti-cancer therapies will be allowed.
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
prior radiation therapy Bone Marrow Percentage | prior radiation therapy Whole-Pelvis | prior radiation therapy Completed | Toxic effect Patient Recovered
Item
prior radiation therapy is allowed to less than 25% of the bone marrow. prior radiation to the whole pelvis is not allowed. prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.
boolean
C0279134 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C3827467 (UMLS CUI [2,2])
C0279134 (UMLS CUI [3,1])
C0205197 (UMLS CUI [3,2])
C0600688 (UMLS CUI [4,1])
C0030705 (UMLS CUI [4,2])
C0521108 (UMLS CUI [4,3])
Item Group
C0680251 (UMLS CUI)
Pregnancy
Item
pregnancy.
boolean
C0032961 (UMLS CUI [1])
Breast Feeding
Item
breast-feeding.
boolean
C0006147 (UMLS CUI [1])
Second Primary Cancer
Item
second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
boolean
C0751623 (UMLS CUI [1])
Aspirin Unable to discontinue Period | Non-Steroidal Anti-Inflammatory Agents Unable to discontinue Period
Item
inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.
boolean
C0004057 (UMLS CUI [1,1])
C1548265 (UMLS CUI [1,2])
C1948053 (UMLS CUI [1,3])
C0003211 (UMLS CUI [2,1])
C1548265 (UMLS CUI [2,2])
C1948053 (UMLS CUI [2,3])
Folate intake Unwilling | Vitamin B12 supplement Intake Unwilling
Item
inability or unwillingness to take folic acid or vitamin b12 supplementation.
boolean
C0564428 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C3661610 (UMLS CUI [2,1])
C1512806 (UMLS CUI [2,2])
C0558080 (UMLS CUI [2,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video